168 related articles for article (PubMed ID: 35456644)
1. Highway to Cell: Selection of the Best Cell-Penetrating Peptide to Internalize the CFTR-Stabilizing iCAL36 Peptide.
Seisel Q; Lakumpa I; Josse E; Vivès E; Varilh J; Taulan-Cadars M; Boisguérin P
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456644
[TBL] [Abstract][Full Text] [Related]
2. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
3. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
4. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
[TBL] [Abstract][Full Text] [Related]
5. Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity.
Roberts KE; Cushing PR; Boisguerin P; Madden DR; Donald BR
PLoS Comput Biol; 2012; 8(4):e1002477. PubMed ID: 22532795
[TBL] [Abstract][Full Text] [Related]
6. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
[TBL] [Abstract][Full Text] [Related]
7. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
8. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
Galietta LJ
Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197
[TBL] [Abstract][Full Text] [Related]
9. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
[TBL] [Abstract][Full Text] [Related]
10. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
11. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR.
Matos AM; Gomes-Duarte A; Faria M; Barros P; Jordan P; Amaral MD; Matos P
Sci Rep; 2018 Aug; 8(1):13026. PubMed ID: 30158635
[TBL] [Abstract][Full Text] [Related]
12. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
[TBL] [Abstract][Full Text] [Related]
13. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
14. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
[TBL] [Abstract][Full Text] [Related]
15. Airway Epithelial Inflammation
Gentzsch M; Cholon DM; Quinney NL; Martino MEB; Minges JT; Boyles SE; Guhr Lee TN; Esther CR; Ribeiro CMP
Front Pharmacol; 2021; 12():628722. PubMed ID: 33859562
[TBL] [Abstract][Full Text] [Related]
16. New horizons in the treatment of cystic fibrosis.
Cuthbert AW
Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
[TBL] [Abstract][Full Text] [Related]
17. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant.
Matos AM; Pinto FR; Barros P; Amaral MD; Pepperkok R; Matos P
J Biol Chem; 2019 Sep; 294(36):13396-13410. PubMed ID: 31324722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]